Design, Development and Screening of Some Novel Quinazolinones for Anticonvulsant Activity

A series of 6-substituted 2-ethyl-3-[substituted benzothiazol-2-yl]-4(3H)-quinazolinones have been synthesized. The structure of all these newly synthesized compounds was confirmed by their elemental(C, H, N) and spectral (IR and 1H NMR) data. The anti-convulsant activity of the title compounds was evaluated by using MES (Maximal Electroshock Method) and subcutaneous pentylenetetrazole (scPTZ) test models in mice. All the test compounds were administered intraperitoneally at a dose 20 mg/Kg body weight and percentage protection were determined. All the experimental protocols were approved by the institutional animal ethical committee (IAEC) and experiments were conducted in accordance with the guidelines provided by the committee for the purpose of control supervision of experimental animals (CPCSEA). All the test compounds showed most prominent anti-convulsant activity with low side effects compared with the reference drug Phenytoin sodium in MES test and Diazepam in scPTZ test.